KMPH stock forecast
Our latest prediction for KemPharm, Inc.'s stock price was made on the Dec. 27, 2019 when the stock price was at 0.42$.
In the short term (2weeks), KMPH's stock price should outperform the market by 2.84%. During that period the price should oscillate between -12.37% and +29.15%.
In the medium term (3months), KMPH's stock price should outperform the market by 0.39%. During that period the price should oscillate between -46.32% and +79.08%.Get email alerts
About KemPharm, Inc.
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
At the moment the company generates 13M USD in revenues.
On its last earning announcement, the company reported a loss of -0.83$ per share.
The book value per share is -5.21$
Three months stock forecastDec. 27, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|